- Trials with a EudraCT protocol (46)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
46 result(s) found for: UGT1A1.
Displaying page 1 of 3.
EudraCT Number: 2016-004576-22 | Sponsor Protocol Number: IRI28 | Start Date*: 2017-07-14 |
Sponsor Name:Catharina Hospital Eindhoven | ||
Full Title: SAFETY, FEASIBILITY AND COST-ANALYSIS OF UGT1A1 GENOTYPE-GUIDED DOSING OF IRINOTECAN | ||
Medical condition: Cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001772-37 | Sponsor Protocol Number: FFCD 0604 | Start Date*: 2007-07-12 |
Sponsor Name:Fédération Francophone de Cancérologie Digestive - FFCD | ||
Full Title: Essai de phase II, multicentrique, évaluant le G-CSF en prophylaxie primaire associé au schéma de chimiothérapie FOLFIRI + bévacizumab en 1ère ligne dans le cancer colorectal métastatique chez des ... | ||
Medical condition: Traitement en 1ère ligne dans le cancer colorectal métastatique chez des patients, homozygotes pour le polymorphisme UGT1A1*28 du promoteur du gène codant pour l’enzyme UGT1A1 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-001275-21 | Sponsor Protocol Number: IriGen | Start Date*: 2013-07-29 | |||||||||||
Sponsor Name:Centre Jean Perrin | |||||||||||||
Full Title: Phase II study: individualization of dosage of irinotecan in the FOLFIRI according to the genetic polymorphism of UGT1A1 in the first line treatment of metastatic colorectal cancer | |||||||||||||
Medical condition: first line metastatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003248-34 | Sponsor Protocol Number: IMPAACTP1110 | Start Date*: 2016-11-02 | |||||||||||
Sponsor Name:NIAID and NICHD | |||||||||||||
Full Title: A PHASE I TRIAL TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF RALTEGRAVIR IN HIV-1-EXPOSED NEONATES AT HIGH RISK OF ACQUIRING HIV-1 INFECTION | |||||||||||||
Medical condition: New born babies at risk of acquiring HIV from their infected mothers. | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000506-37 | Sponsor Protocol Number: GNT-012-CRIG | Start Date*: 2018-04-05 | |||||||||||
Sponsor Name:Genethon | |||||||||||||
Full Title: CareCN: A phase I/II, open label, escalating dose study to evaluate safety and efficacy of an intravenous injection of GNT0003 (Adeno-associated Viral Vector expressing the UGT1A1 transgene) in pat... | |||||||||||||
Medical condition: severe Crigler Najjar syndrome in patients requiring phototherapy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005843-24 | Sponsor Protocol Number: RIFA+UDCA | Start Date*: 2006-02-23 |
Sponsor Name:Hanns-Ulrich Marschall | ||
Full Title: Studie på effekten av rifampicin och ursodeoxycholsyra på gallipider och deras transport och avgiftning hos patienter med kolesterolgallstenar. | ||
Medical condition: Gallstone disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003784-32 | Sponsor Protocol Number: 20050201 | Start Date*: 2007-05-02 | |||||||||||||||||||||
Sponsor Name:Amgen Inc | |||||||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-small Cell Lung Cancer | |||||||||||||||||||||||
Medical condition: Subjects with unresectable stage IIIB with pericardial or pleural effusion or stage IV or recurrent Non Small Cell Lung Cancer (NSCLC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IE (Completed) ES (Completed) AT (Completed) FR (Completed) CZ (Completed) DE (Completed) HU (Completed) IT (Completed) GR (Completed) SK (Completed) BG (Completed) GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001559-20 | Sponsor Protocol Number: 95195608 | Start Date*: 2007-04-17 |
Sponsor Name:Cliniques Universitaires Saint-Luc | ||
Full Title: Steady-state pharmacokinetics of high dose acetaminophen inpost-op children. Rational use of N-acetyl cysteine for prevention of liver toxicity related to cumulative doses. | ||
Medical condition: Major surgery when the use of paracetamol is required for pain release | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-000221-42 | Sponsor Protocol Number: IIBSP-IRI-2011-134 | Start Date*: 2012-05-03 |
Sponsor Name:Fundación Institut de Recerca Hospital Sant Pau | ||
Full Title: Estudio farmacogenético fase II randomizado para evaluar la eficacia y seguridad del esquema FOLFIRI con altas dosis de irinotecán (FOLFIRI-AD) en pacientes con cáncer colorrectal metastásico de a... | ||
Medical condition: metastatic colorectal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2008-007948-34 | Sponsor Protocol Number: ANRS 144 | Start Date*: 2009-02-27 | |||||||||||
Sponsor Name:Agence nationale de recherches sur le sida et les hépatites virales. ANRS. | |||||||||||||
Full Title: Essai randomisé en double insu comparant l’efficacité et la tolérance du tartrate de varénicline versus placebo dans l’aide à l’arrêt de la consommation de tabac chez les patients infectes infectés... | |||||||||||||
Medical condition: Sevrage tabagique chez les patients VIH+ "tobacco user" | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001972-19 | Sponsor Protocol Number: Feno Atorva | Start Date*: 2007-01-22 | |||||||||||
Sponsor Name:Hanns-Ulrich Marschall | |||||||||||||
Full Title: Study of atorvastatin and fenofibrate mediated effects on the metabolism and hepatic excretion of biliary compounds in gallstone patients. | |||||||||||||
Medical condition: Gallstone disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001459-17 | Sponsor Protocol Number: NuTide:323 | Start Date*: 2023-03-27 | |||||||||||
Sponsor Name:NuCana plc | |||||||||||||
Full Title: A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev)... | |||||||||||||
Medical condition: Relapsed, unresectable, histologically or cytologically confirmed metastatic adenocarcinoma of colon or rectum with radiologically measurable disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003779-20 | Sponsor Protocol Number: SCO101-001 | Start Date*: 2020-01-28 | |||||||||||
Sponsor Name:Scandion Oncology A/S | |||||||||||||
Full Title: An open-label phase II prospective clinical trial to investigate safety, tolerability, maximum tolerated dose and anti-tumor effect for SCO-101 in combination with FOLFIRI as a safe and efficient t... | |||||||||||||
Medical condition: Metastatic or advanced colorectal cancer (mCRC) with acquired resistance to chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003292-42 | Sponsor Protocol Number: 20060534 | Start Date*: 2008-12-02 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 1b/ 2 Trial of AMG 479 or AMG 102 in Combination with Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer | |||||||||||||
Medical condition: Previously Untreated Extensive Stage Small Cell Lung Cancer (SCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) NL (Completed) PL (Completed) CZ (Completed) HU (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002766-20 | Sponsor Protocol Number: CAUY922A2101 | Start Date*: 2009-02-25 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A phase I dose escalation, multi-center, open-label study of AUY922 administered IV on a once-weekly schedule in adult patients with advanced solid malignancies including phase II expansion arms in... | ||
Medical condition: Dose-expansion study to assess safety, tolerability & efficacy: -One arm (MTD expansion) will enroll advanced cancer patients (other than breast carcinoma). -Two arms (phase II) to assess response ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001201-24 | Sponsor Protocol Number: KRT-232-104 | Start Date*: 2019-12-02 | |||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML). | |||||||||||||
Medical condition: Relapsed or refractory AML, AML secondary to myeloproliferative neoplasms (MPN), and JAK2 mutationpositive AML. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) BE (Prematurely Ended) HU (Completed) PL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014876-23 | Sponsor Protocol Number: EZN-2208-04 | Start Date*: 2010-05-20 | |||||||||||
Sponsor Name:Enzon Pharmaceuticals, Inc | |||||||||||||
Full Title: A Phase 2 Study of EZN-2208 (PEG-SN38) Administered With or Without Cetuximab in Patients with Metastatic Colorectal Carcinoma (mCRC) | |||||||||||||
Medical condition: mestatic colorectal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005074-12 | Sponsor Protocol Number: 20070411 | Start Date*: 2009-03-04 | |||||||||||||||||||||
Sponsor Name:Amgen Inc | |||||||||||||||||||||||
Full Title: A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination with AMG 479 in Subjects with Advanced, Refractory Solid Tumors. -------------------------------------------------------- Es... | |||||||||||||||||||||||
Medical condition: Part 1: Advanced, treatment-refractory solid tumors Part 2: Advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, ovarian cancer, or sarcoma. --------------------... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-015459-25 | Sponsor Protocol Number: CTKI258A2302 | Start Date*: 2010-12-01 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angioge... | |||||||||||||
Medical condition: metastatic renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) NL (Completed) BE (Completed) ES (Completed) HU (Completed) SK (Completed) IT (Completed) DE (Completed) SE (Completed) AT (Completed) GR (Completed) GB (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000451-41 | Sponsor Protocol Number: HO150 | Start Date*: 2019-03-01 | ||||||||||||||||
Sponsor Name:HOVON Foundation | ||||||||||||||||||
Full Title: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therap... | ||||||||||||||||||
Medical condition: AML or MDS-EB2 with a mutation in either IDH1 or IDH2 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Trial now transitioned) FI (Trial now transitioned) LT (Trial now transitioned) SE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
